Mabel
Mabel
My name is Mabel. I was diagnosed with acute myeloid leukemia (AML) in December 2018. I started aggressive treatment at Northside Hospital in Atlanta, GA.
Jackson
Jackson
Life for Rachael, Brandon, and Jackson was good. Jackson was a happy and healthy baby. He loved all things trucks, looking at books, helping his dad with projects around the house, and playing with his puppy Remy. In the weeks leading up to his second birthday, Jackson developed a low-grade fever that he just couldn’t shake.
Acute Leukemia and Myeloid Malignancies Rounds Chicago
Ballrooms A/B and C/D
25 South Halsted Street
Chicago, IL 60661
United States
*Pre-Registration Required
Live In-Person Event
Interactive continuing medical education activity for healthcare professionals in Chicago and surrounding areas to discuss acute leukemia and myeloid malignancies updates and challenges in treatment.
This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with acute leukemia and myeloid malignancies.
Agenda
5:30 PM – Dinner and networking
6:30 PM – 6:30 PM – Welcome, program overview, and updates in clinical trials
Himachandana Atluri, MD
6:40 PM – Overview of Blood Cancer United resources
Lauren Berger, MPH
6:45 PM – Case presentation and discussion on the treatment of NPM1-mutated AML in an older, fit patient - intensive vs. non-intensive induction and consideration of menin inhibition
Noah Birch, MD, PhD, Stephanie B. Tsai, MD, and TBA
7:15 PM – Case presentation and discussion on low-risk and high-risk MDS treatment
Himachandana Atluri, MD, Max Kelsten, MD, Amy Wang, MD, and Sanja Zepcan, PharmD, BCPS
7:45 PM – Case presentation and discussion on CAR-T and ALL
Melissa L. Larson, MD, Gregg Roloff, MD and TBA
8:15 PM – Discussion and wrap-up
All Faculty
8:30 PM – Conclusion
Himachandana Atluri, MD
Learning Objectives
At the conclusion of this activity, participants will be better able to:
- Explain the most recent data on novel treatment options in acute leukemias and myeloid malignancies
- Discuss drug interactions with novel therapies and how to manage
- Explain diagnostic and prognostic testing and challenges, relapse prevention and detection of measurable residual disease
- Explain disparities and challenges in the diagnosis and treatment of acute leukemias and myeloid malignancies
- Identify resources for patient education and support
ADVISORY GROUP
Himachandana Atluri, MD (Chair)
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Taha Alrifai, MD
Advocate Health Care
Park Ridge, IL
Jessica Altman, MD
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Noah Birch, MD, PhD
University of Illinois Chicago (UIC)
Chicago, IL
Keriann Kordas, MSN, APN
The University of Chicago Medicine & Biological Sciences
Chicago, IL
Melissa L. Larson, MD
Rush University Medical Center
Chicago, IL
Adam Robinson, PharmD, BCOP
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Gregory Roloff, MD
UChicago Medicine
Chicago, IL
Stephanie B. Tsai, MD
Loyola University Medical Center
Maywood, IL
Olatoyosi Odenike, MD, FASCO
The University of Chicago
Chicago, IL
Amy Wang, MD
Endeavor Health
Evanston, IL
Sanja Zepcan, PharmD, BCPS
Loyola University Medical Center
Maywood, IL
FACULTY
Himachandana Atluri, MD (Chair)
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
Lauren Berger, MPH
Blood Cancer United
Washington, DC
Noah Birch, MD, PhD
University of Illinois Chicago (UIC)
Chicago, IL
Max Kelsten, MD
Northwestern University
Chicago, IL
Melissa L. Larson, MD
Rush University Medical Center
Chicago, IL
Gregory Roloff, MD
UChicago Medicine
Chicago, IL
Stephanie B. Tsai, MD
Loyola University Medical Center
Maywood, IL
Amy Wang, MD
Endeavor Health
Evanston, IL
Sanja Zepcan, PharmD, BCPS
Loyola University Medical Center
Maywood, IL
Additional Faculty TBA
Accreditation, Credit and Support
In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development Contact Hours
Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 2.0 continuing education contact hours through the California Board of Registered Nursing.
Pharmacy
Medical Learning Institute Inc designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-25-037-L01-P
For Pharmacists, Medical Learning Institute Inc will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/
Interprofessional Continuing Education Credit
This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Method of Participation
There are no fees for participating in or receiving credits for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form, and return it to staff at the end of the program. A certificate of completion will be emailed within 30 days of receipt. If you have questions regarding the receipt of your certificate, please contact us via email at [email protected].
Providers
This activity is provided by Blood Cancer United and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).
Supporters
Blood Cancer United thanks Autolus Therapeutics, Geron Corporation, and Novartis Pharmaceuticals Corporation for their financial support.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at [email protected].
Nicholas
Nicholas
It started with a stiff neck. Then came fatigue and a sore throat. I started feeling full after only a few bites of food. Workouts were getting more difficult to complete. My heart rate was consistently north of 100 just lying in bed. Rationalized. It's maybe strep. Could be mono. I prescribed myself antibiotics and popped ibuprofen. Nothing was working.
Abelina
Abelina
I was diagnosed with acute myeloid leukemia (AML) while 26 weeks pregnant at 35 years old. I remember looking in the mirror one day and told my husband I looked like I was sick, but we just chalked it up to me being pregnant. A few weeks later, I found a rash on my legs and scheduled an appointment with my OB who ordered bloodwork.
Abby
Abby
I was diagnosed with acute myeloid leukemia (AML) at the age of 22 in April 2024. I am a mom to a now two-year-old who I had to be apart from for four months to get treatment.